Sabinsa’s Curcumin C3 Complex, the number one clinically studied curcumin brand on the market, is the subject of a recently published study on its effect, combined with BioPerine, on serum cytokine concentrations.
Effects of supplementation with curcuminoids on serum adipokines in critically ill patients: a randomised double-blind placebo-controlled trial was published in the peer-reviewed journal Phytotherapy Research.
In this clinical trial, researchers studied the effects of the administration of Curcumin C3 Complex and BioPerine in combination on the levels of the cytokines leptin and adiponectin in critically ill patients with traumatic brain injury (TBI).
In a total of 62 patients, supplementation with 500 mg of C3 Complex and 5 mg of BioPerine daily showed a statistically significant decrease in the proinflammatory cytokine leptin in the treatment group compared with the placebo group.
Although leptin is often associated with food intake and energy expenditure, its importance in ageing conditions, serious illness and stressful injuries is increasingly recognised.
Simultaneously the researchers also monitored the levels of the beneficial anti-inflammatory cytokine adiponectin.
They commented that the increase in adiponectin did not reach statistical significance, presumably owing to the short 7-day duration of this trial. They also pointed to other trial results in which longer durations of curcuminoids administration resulted in adiponectin level increases.
“We are happy to see the utility of C3 Complex with BioPerine in controlling the expression of cytokines in TBI patients,” said Sabinsa founder and Chairman Dr Muhammed Majeed. “It is heartening to note that there were only benefits and no adverse side effects for this group of subjects, further attesting to our ingredient's safety.”
